Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.
Nonalcoholic fatty liver disease (NAFLD) is becoming rapidly one of the most common indications for orthotopic liver transplantation in the world. Development of graft steatosis is a significant problem during the post-transplant course, which may happen as a recurrence of pre-existing disease or de novo NAFLD. There are different risk factors that might play a role in development of graft steatosis including post-transplant metabolic syndrome, immune-suppressive medications, genetics and others. There are few studies that assessed the effects of NAFLD on graft and patient survival; most of them were limited by the duration of follow up or by the number of patients. With this review article we will try to shed light on post-liver transplantation NAFLD, significance of the disease, how it develops, risk factors, clinical course and treatment options.
Mina Shaker, Adam Tabbaa, Mazen Albeldawi, Naim Alkhouri, Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, OH 44195, United States.
Mina
M
Shaker
Mina Shaker, Adam Tabbaa, Mazen Albeldawi, Naim Alkhouri, Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, OH 44195, United States.
Adam
A
Tabbaa
Mina Shaker, Adam Tabbaa, Mazen Albeldawi, Naim Alkhouri, Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, OH 44195, United States.
Mazen
M
Albeldawi
Mina Shaker, Adam Tabbaa, Mazen Albeldawi, Naim Alkhouri, Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, OH 44195, United States.
Naim
N
Alkhouri
D020022:Genetic Predisposition to Disease; D006085:Graft Survival; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis / Q000235:genetics / Q000601:surgery*; D010641:Phenotype; D011183:Postoperative Complications / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D012008:Recurrence; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
Liver cirrhosis; Liver transplantation; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis